|Bid||3.7000 x 36200|
|Ask||3.6400 x 3200|
|Day's Range||3.3800 - 3.7300|
|52 Week Range||2.0900 - 15.8640|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 15, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.41|
Subscribe to Yahoo Finance Plus to view Fair Value for DNA
Ginkgo is teaming up with Synlogic to launch a new gout drug, moving shares of both stocks higher.
Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced a new drug candidate for the treatment of gout developed in partnership with Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming. The new candidate, SYNB2081, is a Synthetic Biotic and is the second product to advance to clinical development through a research collab
Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, and the Rwanda Development Board ("RDB"), representing the government of the Republic of Rwanda, today announced that they have entered into a Memorandum of Understanding ("MOU") with the intent of developing and implementing new biosecurity capabilities in Rwanda.